FREAMINE III 8.5%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FREAMINE III 8.5% (FREAMINE III 8.5%).
FREAMINE III 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, nitrogen balance maintenance, and tissue repair. It acts as a substrate for protein anabolism in patients unable to tolerate adequate oral or enteral intake.
| Metabolism | Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle reactions. Some branched-chain amino acids undergo peripheral metabolism in muscle tissue. |
| Excretion | Renal: 90-95% of infused amino acids are reabsorbed; excess nitrogen excreted as urea (80-90% of nitrogen load) and ammonia (<10%). Biliary/fecal: negligible (<5%). |
| Half-life | Terminal elimination half-life of infused amino acids is approximately 15-30 minutes for most, but albumin synthesis half-life is 20-22 days; clinical context: continuous infusion needed for nitrogen balance. |
| Protein binding | Minimal; amino acids are not significantly protein-bound (<10% bound to albumin for some, but not clinically relevant). |
| Volume of Distribution | Vd approximately 0.4-0.5 L/kg (total body water); reflects distribution into extracellular and intracellular compartments. |
| Bioavailability | Intravenous: 100% (only route; not administered orally due to incomplete absorption and first-pass metabolism). |
| Onset of Action | Intravenous: nitrogen retention and positive nitrogen balance observed within 24-48 hours; protein synthesis stimulation begins within hours. |
| Duration of Action | Duration of nitrogen-sparing effect is 4-6 hours after infusion cessation; sustained effects on protein synthesis require continuous or repeated administration. |
Intravenous infusion; typical adult dose is 0.8-1.5 g amino acids/kg/day (equivalent to 9.4-17.6 mL/kg/day of Freamine III 8.5%). Initiate at lower end and titrate to metabolic needs. Administer via central or peripheral line with dextrose and electrolytes as part of parenteral nutrition.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-59 mL/min: reduce dose by 50% of standard; for GFR <30 mL/min: use 0.5-0.8 g amino acids/kg/day with close monitoring. In dialysis patients, adjust based on nutritional status and dialysis losses; consider higher doses (1.2-1.5 g/kg/day) with careful fluid and electrolyte management. |
| Liver impairment | Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 25-50% and monitor ammonia; Child-Pugh C: avoid use or use with extreme caution at 0.5-0.8 g/kg/day with frequent ammonia monitoring. In hepatic encephalopathy, use specialized amino acid formulations. |
| Pediatric use | Neonates and infants: 1.5-3 g amino acids/kg/day; children: 1-2 g/kg/day; adolescents: 0.8-1.5 g/kg/day. Administer as continuous infusion with appropriate non-protein calories. Adjust based on metabolic tolerance and growth parameters. |
| Geriatric use | No specific dose adjustment; use with caution due to potential renal and hepatic impairment. Initiate at lower end of adult dosing (0.8-1 g/kg/day) and titrate slowly. Monitor fluid, electrolyte, and metabolic status closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FREAMINE III 8.5% (FREAMINE III 8.5%).
| Breastfeeding | Amino acids are endogenous substances and are present in breast milk. Intravenous infusion results in increased maternal plasma concentrations, which may lead to higher milk concentrations. The M/P ratio is unknown. Use during breastfeeding is considered compatible with lactation under medical supervision, as amino acids are normal milk components. However, monitor for potential infant electrolyte or metabolic disturbances if high doses are used. |
| Teratogenic Risk | Amino acid infusions are generally considered safe during pregnancy when administered for maternal nutritional support. There is no evidence of teratogenic risk in the first trimester; however, maternal metabolic disturbances (e.g., electrolyte imbalances, acidosis) may affect fetal development. In the second and third trimesters, amino acid infusions are used to support fetal growth without documented increased malformation risk, but caution is advised due to potential effects on fetal acid-base balance. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component of the solution, severe liver disease with hyperammonemia, inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria), untreated anuria, and severe hypervolemic states.
| Precautions | Monitor serum electrolytes, fluid balance, and renal function closely. Risk of hypervolemia, electrolyte imbalances, and metabolic acidosis. Use with caution in patients with heart failure, renal insufficiency, or hepatic impairment. Ensure proper central venous access to avoid extravasation. Do not administer simultaneously with blood through the same infusion set due to risk of precipitation. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, acid-base status, blood glucose, liver function, and renal function. Monitor fetal heart rate and growth in prolonged use or with maternal metabolic instability. Assess for signs of maternal fluid overload, hyperammonemia, or hyperglycemia. |
| Fertility Effects | No known direct adverse effects on fertility. Restoration of nutritional status in malnourished women may improve fertility. However, underlying conditions requiring parenteral nutrition may be associated with reproductive dysfunction. |